Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market

Posted on
by

Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market
Postpartum Depression market growth
The Postpartum Depression market growth is driven by factors like increase in the prevalence of Postpartum Depression, investments in research and development, entry of emerging therapies during the study period 2020-2034.

The Postpartum Depression market report also offers comprehensive insights into the Postpartum Depression market size, share, Postpartum Depression epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Postpartum Depression market size growth forward.

Some of the key highlights from the Postpartum Depression Market Insights Report:

  • Several key pharmaceutical companies, including Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others, are developing novel products to improve the Postpartum Depression treatment outlook.

  • In February 2024, the US Department of Health and Human Services (HHS), along with HHS leaders, engaged with state officials and the National Governors Association (NGA) to announce the launch of the HHS Secretary’s Postpartum Maternal Health Collaborative. This initiative aims to enhance maternal and child health in rural America.

  • In December 2023, the Centers for Medicare & Medicaid Services introduced the new Transforming Maternal Health (TMaH) Model. This model focuses on improving access to care, building infrastructure and workforce capacity, enhancing quality and safety, and promoting whole-person care delivery.

  • In August 2023, the American Psychiatric Association released new educational resources on maternal mental health. These resources include a toolkit with eight fact sheets for both clinicians and patients, a white paper, and a four-part webinar series addressing this often overlooked area of mental health.

  • The Postpartum Depression (PPD) treatment market in the 7MM was valued at USD 260 million in 2023. Among the EU4 and the UK, the UK had the highest market size for PPD, reaching approximately USD 25 million in 2023. Across the seven major markets, there were around 1,310,000 diagnosed prevalent cases of Postpartum Depression in 2023, with about 460,000 of these cases occurring in females in the EU4 and the UK.

  • Postpartum Depression is the most common non-psychotic complication affecting women after childbirth, potentially disrupting maternal-infant bonding and negatively impacting both immediate and long-term child development. It is diagnosed when at least five depressive symptoms persist for two or more weeks. According to the DSM-5, PPD is identified as a major depressive episode with peripartum onset, though it is not listed as a separate disorder.

  • Screening for PPD is typically conducted 2 to 6 months postpartum, with women also assessed for manic symptoms. The Edinburgh Postnatal Depression Scale (EPDS) is one of the most widely used screening tools. Selective serotonin reuptake inhibitors (SSRIs) are the primary treatment choice, and a combination of antidepressants and therapy is recommended for moderate to severe cases.

  • ZURZUVAE (zuranolone) and ZULRESSO (brexanolone) are the only FDA-approved treatments for PPD. Zulresso is administered via continuous intravenous infusion, while ZURZUVAE is taken orally for 14 days at a dosage of 50 mg. Key players in the development of new PPD therapies include Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences.

  • Several major companies are leading the Postpartum Depression treatment landscape, including Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, Brii Biosciences, and others. Below are the details of the Postpartum Depression market size by country and therapy.

  • The Postpartum Depression treatment market in the 7MM was valued at approximately USD 260 million in 2023. In the seven major markets for Postpartum Depression therapeutics, SNRIs and SSRIs accounted for 20% of the overall market share, while atypical antidepressants and antipsychotics held a 19% share in 2023.

  • By 2034, ZURZUVAE is projected to generate around USD 600 million in revenue from the Postpartum Depression therapeutics market in the 7MM.

  • As per DelveInsight analysis, the Postpartum Depression market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Postpartum Depression Market Landscape

Postpartum Depression Overview

Postpartum depression (PPD) is the most prevalent non-psychotic complication during the childbearing period, affecting about 10-15% of women, and represents a significant public health issue impacting both women and their families. The postnatal period is widely recognized as a time of increased vulnerability for developing severe mood disorders. There are three main types of postpartum mood disorders: the baby blues (maternity blues), postpartum depression, and puerperal psychosis, each varying in prevalence, clinical symptoms, and treatment. The impact of postnatal depression on the mother, her relationship with her partner, and her children makes it crucial to diagnose, treat, and prevent this condition. If left untreated, PPD can lead to long-term negative effects, including chronic recurrent depression in the mother and emotional, behavioral, cognitive, and social issues in her children.

The link between the postpartum period and mood disturbances has been recognized since the time of Hippocrates. Research shows that women are at an increased risk of severe psychiatric conditions during the puerperium. In fact, studies indicate that women are more likely to be admitted to psychiatric hospitals in the first month after childbirth than at any other time. Approximately 12.5% of all psychiatric hospital admissions for women occur during the postpartum period.

Do you know the treatment paradigms for different countries? Download our Postpartum Depression Market Sample Report

Postpartum Depression Epidemiology Segmentation

DelveInsight’s Postpartum Depression market report is prepared on the basis of an epidemiology model. It offers comprehensive insights to the Postpartum Depression historical patient pools and forecasted Postpartum Depression patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Postpartum Depression Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

  • Postpartum Depression Prevalence

  • Age-Specific Postpartum Depression Prevalence

  • Gender-Specific Postpartum Depression Prevalence

  • Diagnosed and Treatable Cases of Postpartum Depression

Visit for more @ Postpartum Depression Epidemiological Insights

Postpartum Depression Market Outlook

Antidepressants such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) are central to the treatment of Postpartum Depression (PPD). While these medications are approved for conditions like major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), and treatment-resistant depression (TRD), they are commonly used off-label for PPD. The choice of medication largely depends on the symptoms, severity, and specific type of PPD the patient is experiencing. A key concern with antidepressants is the uncertain outcomes and potential side effects on newborns due to breastfeeding. Although antidepressants do not offer a permanent cure for PPD, they play a crucial role in managing depressive symptoms and improving the quality of life.

New therapies with innovative mechanisms, such as GABAA receptor positive allosteric modulators and allosteric modulators of the GABA receptor, are being developed by companies like Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences for PPD treatment.

In conclusion, despite the current lack of adequate treatments for Postpartum Depression, many promising therapies with novel mechanisms are expected to enter the market, addressing a significant unmet need in PPD care and greatly improving treatment outcomes. As new treatment options become available and healthcare spending increases across the 7MM, the Postpartum Depression treatment market is projected to experience substantial growth during the forecast period (2024–2034).

Postpartum Depression Marketed Drugs

  • ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen

  • ZULRESSO: Sage Therapeutics

Postpartum Depression Emerging Drugs

  • Ganaxolone: Marinus Pharmaceuticals

Postpartum Depression Key Companies

  • Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, and others

For more information, visit Postpartum Depression Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Postpartum Depression Market Report:

  • 11 Years Forecast

  • 7MM Coverage

  • Descriptive overview of Postpartum Depression, causes, signs and symptoms, diagnosis, treatment

  • Comprehensive insight into Postpartum Depression epidemiology in the 7MM

  • Postpartum Depression marketed and emerging therapies

  • Postpartum Depression companies

  • Postpartum Depression market drivers and barriers

Table of Contents:

1 Postpartum Depression Market Key Comprehensive Insights

2 Postpartum Depression Market Report Introduction

3 Competitive Intelligence Analysis for Postpartum Depression

4 Postpartum Depression Market Analysis Overview at a Glance

5 Executive Summary of Postpartum Depression

6 Postpartum Depression Epidemiology and Market Methodology

7 Postpartum Depression Epidemiology and Patient Population

8 Postpartum Depression Patient Journey

9 Postpartum Depression Treatment Algorithm, Postpartum Depression Current Treatment, and Medical Practices

10 Key Endpoints in Postpartum Depression Clinical Trials

11 Postpartum Depression Marketed Therapies

12 Postpartum Depression Emerging Therapies

13 Postpartum Depression: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Postpartum Depression

16 Postpartum Depression Market Key Opinion Leaders Reviews

18 Postpartum Depression Market Drivers

19 Postpartum Depression Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Postpartum Depression Epidemiology 2034

DelveInsight’s “Postpartum Depression – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Postpartum Depression epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Postpartum Depression Pipeline 2024

“Postpartum Depression Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Postpartum Depression market. A detailed picture of the Postpartum Depression pipeline landscape is provided, which includes the disease overview and Postpartum Depression treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/